Timeline › Low-rate stagnation
FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005
Draft: not yet verifiedScience, invention & breakthrough technologyDemographics & society
Why it matters
The GLP-1 class moves from diabetes to obesity
- Era
- Low-rate stagnation (2013–19)
- Track
- Technology & science
- Asset classes
- Equities
- Verify via
- FDA
- Wikipedia
- Semaglutide (article on this event)
- Date check
- no date in Wikidata
Open in the interactive timeline, with its macro chartsSuggest a correction
Sources
References cited in the Wikipedia article, official and academic ones first.
- FDA Approves Treatment for Serious Liver Disease Known as 'MASH' — U.S. Food and Drug Administration (FDA) (2025) (Official)
- FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 — U.S. Food and Drug Administration (FDA) (2014) (Official)
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight — U.S. Food and Drug Administration (FDA) (2024) (Official)
- Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular out — Diabetes, Obesity & Metabolism (2020) (Academic)
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications — U.S. Food and Drug Administration (FDA) (2024) (Official)
Connected events
Events whose Wikipedia articles link to this one. Links show relatedness, not cause.
- 1 June 1998 European Central Bank established · Euro area / EU
Single monetary policy
Previous and next events on the Technology & science track.
Cite this event
Wang, Y. (2026). FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005 (5 December 2017). In Macro-financial history, 1900–2026, event E0448. https://macrofinancialhistory.com/event/e0448/
@misc{mefh_e0448,
author = {Wang, Yuhui},
title = {FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005},
howpublished = {Macro-financial history, 1900–2026, event E0448},
year = {2026},
url = {https://macrofinancialhistory.com/event/e0448/}
}